IRIS
MINOTTI, GIORGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 9.279
NA - Nord America 4.209
EU - Europa 1.760
SA - Sud America 531
Continente sconosciuto - Info sul continente non disponibili 180
AF - Africa 68
OC - Oceania 34
Totale 16.061
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 6.302
US - Stati Uniti d'America 4.015
CN - Cina 1.290
HK - Hong Kong 998
IT - Italia 740
BR - Brasile 375
GB - Regno Unito 259
FR - Francia 222
VN - Vietnam 212
DE - Germania 155
BD - Bangladesh 134
IN - India 93
CA - Canada 88
CZ - Repubblica Ceca 72
MX - Messico 65
NL - Olanda 62
AR - Argentina 54
RU - Federazione Russa 42
ID - Indonesia 39
FI - Finlandia 34
AU - Australia 32
JP - Giappone 28
IQ - Iraq 25
EC - Ecuador 24
UA - Ucraina 24
BE - Belgio 22
ES - Italia 22
TR - Turchia 22
CO - Colombia 20
ZA - Sudafrica 19
PL - Polonia 18
PY - Paraguay 18
CL - Cile 15
MY - Malesia 15
SA - Arabia Saudita 15
MD - Moldavia 13
PK - Pakistan 13
PH - Filippine 12
PE - Perù 10
VE - Venezuela 10
AE - Emirati Arabi Uniti 9
JM - Giamaica 9
JO - Giordania 9
SE - Svezia 9
TN - Tunisia 9
UZ - Uzbekistan 9
CR - Costa Rica 8
EE - Estonia 8
MA - Marocco 8
TW - Taiwan 8
AL - Albania 7
NP - Nepal 7
PT - Portogallo 7
EG - Egitto 6
LT - Lituania 6
AT - Austria 5
HU - Ungheria 5
RO - Romania 5
DO - Repubblica Dominicana 4
TH - Thailandia 4
AO - Angola 3
AZ - Azerbaigian 3
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
GE - Georgia 3
GT - Guatemala 3
HR - Croazia 3
IE - Irlanda 3
IL - Israele 3
IR - Iran 3
KR - Corea 3
KW - Kuwait 3
NA - Namibia 3
UY - Uruguay 3
BO - Bolivia 2
BY - Bielorussia 2
DM - Dominica 2
DZ - Algeria 2
ET - Etiopia 2
GA - Gabon 2
HN - Honduras 2
KG - Kirghizistan 2
KN - Saint Kitts e Nevis 2
KZ - Kazakistan 2
LV - Lettonia 2
LY - Libia 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
PR - Porto Rico 2
SI - Slovenia 2
SN - Senegal 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AG - Antigua e Barbuda 1
AM - Armenia 1
BF - Burkina Faso 1
BH - Bahrain 1
Totale 15.860
Salva come PNG Salva come JPEG
Città #
San Jose 1.261
Hong Kong 989
Singapore 814
Ashburn 739
Rome 549
Hefei 455
Beijing 313
Council Bluffs 307
Boardman 269
Columbus 234
London 205
Lauterbourg 199
Shanghai 149
Dallas 121
Santa Clara 92
Ho Chi Minh City 71
Munich 71
Los Angeles 70
San Francisco 59
Redmond 56
Brno 54
New York 54
Hanoi 44
Amsterdam 43
São Paulo 38
Pune 37
Mexico City 33
Toronto 32
Washington 22
Seattle 20
Brooklyn 19
Turku 19
Haiphong 18
Chicago 17
Melbourne 17
Olomouc 17
Hasselt 16
Tokyo 16
West Jordan 16
Helsinki 14
Atlanta 13
Rio de Janeiro 13
The Dalles 13
Warsaw 13
Boston 12
Frankfurt am Main 12
Guangzhou 12
Quito 12
Buffalo 11
Chennai 11
Manchester 11
Phoenix 11
Canberra 10
Orem 10
Catania 9
Johannesburg 9
New Delhi 9
Nuremberg 9
Palermo 9
Riyadh 9
Amman 8
Asunción 8
Biên Hòa 8
Bogotá 8
Fortaleza 8
Hangzhou 8
Kuala Lumpur 8
Las Vegas 8
Milan 8
San José 8
Tashkent 8
Bengaluru 7
Brasília 7
Buenos Aires 7
Da Nang 7
Dhaka 7
Lima 7
Montreal 7
Paris 7
Ankara 6
Baghdad 6
Belo Horizonte 6
Campinas 6
Charlotte 6
Haikou 6
Oklahoma City 6
Philadelphia 6
Poplar 6
Caracas 5
Curitiba 5
Denver 5
Formosa 5
Hanover 5
Moscow 5
Santiago 5
Shenzhen 5
Staten Island 5
Stockholm 5
Sulaymaniyah 5
Sydney 5
Totale 8.045
Salva come PNG Salva come JPEG
Nome #
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 233
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 228
Proceedings of an International Workshop on Anthracycline Cardiotoxicity 212
An investigation into thee mechanism of citrateFE2+-dependent lipid peroxidation 211
Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study. 210
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 208
Altered iron regulatory protein activities in doxorubicin-treated cardiomyocytes : Distinct roles of reactive oxygen species and of the secondary alcohol metabolite doxorubicinol 208
Cancer drugs and QT prolongation: weighing risk against benefit 207
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 207
A supposed role for superoxide dismutase in the control of tumor growth 206
Cell Biology and Toxicology: Special Issue on Cardiovascular Liability of Drugs 206
Minimal sampling colistin pharmacokinetics in critically ill patients 204
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 202
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 197
A Special Section on Clinical Pharmacology-Editorial 195
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 195
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 194
Acute Heart Failure 29 Years After Treatment for Childhood Cancer 193
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines 193
Adriamycin dependent release of iron from human lung tumor microsomes : Biochemical mechanisms and clinical implications 190
Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes 185
Cardio-oncology in clinical studies and real life 185
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 182
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 180
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 158
Anthracycline Cardiotoxicity 141
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 139
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). 139
Anthracycline metabolism and toxicity in human myocardium : Comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with reduced formation and [4Fe-4S]-reactivity of its secondary alcohol metabolite 132
Anthracyclines 127
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 125
Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study 125
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite 125
Anthracycline Cardiotoxicity 115
An Invitation from the Editors of Cardio-Oncology 112
Adriamycin dependent release of iron from microsomal membranes 111
Activation of heme oxygenase and consequent carbon monoxide formation inhibits the release of arginine vasopressin from rat hypothalamic explants. Molecular linkage between heme catabolism and neuroendocrine function. Mol Brain Res. 109
Anthracycline cardiotoxicity 109
Adriamycin alcohol dependent iron mobilization : A novel mechanism of adriamycin cardiotoxicity? 107
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 107
All Eyes on Me, Please: Ocular Palonosetron for the Cancer Patient with Nausea and Vomiting 105
An introduction to the metabolic determinants of anthracycline cardiotoxicity 105
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 101
Cardiotoxicity of antitumor drugs 101
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny 97
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 93
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 90
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 89
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement 80
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 79
The interaction of short chain coenzyme Q analogs with different redox states of myoglobin 75
Superoxide-dependent lipid peroxidation and vitamin E content of microsomes from hepatomas with different growth rates. 72
Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma 72
Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death 72
Isavuconazole: case report and pharmacokinetic considerations 71
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology. 71
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 68
Pharmacology of Cardio-Oncology 68
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 67
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 67
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 66
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 66
Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond 65
What is cardiotoxicity? 64
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 64
Novel mechanisms for the inhibition of low density lipoprotein oxidation by ascorbic acid. 63
Doxorubicin-Dexrazoxane from day 1 for soft-tissue sarcomas: The road to cardioprotection 63
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 62
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 62
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 62
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 62
Post-transcriptional control of hepatic oxidative stress respone 62
Early diagnosis of acute coronary syndrome. 62
Safety and tolerability of a novel oral nutritional supplement in healthy volunteers 62
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 60
Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases 60
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 59
Vitamin E inhibits enhanced F2 isoprostane biosynthesis in type IIA hypercholesterolemia excretion 59
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 59
Drug-induced hepatotoxicity in cancer patients - implication for treatment 59
Cancer incidence and mortality in patients diagnosed with heart failure: results from an updated systematic review and meta-analysis 58
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium 58
Anthracycline secondary alcohol metabolite formation in human or rabbit heart ; Biochemical aspects and pharmacological implications 58
Cardiotoxicity of antitumor drugs 58
Nitric oxide and peroxynitrite activate the iron regulatory protein-1 of J774A.1 macrophages by direct disassembly of the Fe-S cluster of cytoplasmic aconitase 58
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib. 58
Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence 57
Quantitative evaluation of the activity of the malate-aspartate shuttle in Ehrlich ascites tumor cells. 57
Pharmacological Foundation of Cardio-Oncology 57
Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. 57
Cardiovascular Toxicity of non cardiovascular drugs 57
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 57
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 56
Development of a tumor-specific photoactivatable doxorubicin prodrug. 56
Doxorubicin toxicity in human heart: role of C-13 metabolite, c-aconitase and iron 56
Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin 56
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 55
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 55
The [Fe-S] cluster of cytoplasmic aconitase as a novel target of anthracycline cardiotoxicity 55
Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity 55
Totale 10.830
Salva come PNG Salva come JPEG
Categoria #
all - tutte 115.651
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 115.651
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022527 0 5 0 1 0 1 2 214 7 7 7 283
2022/2023108 2 4 5 8 7 5 13 0 2 7 51 4
2023/2024776 22 87 29 55 96 329 9 29 6 24 10 80
2024/20257.426 150 67 268 29 72 168 91 32 690 586 2.541 2.732
2025/20266.565 714 289 311 693 260 348 1.881 527 504 525 267 246
2026/2027659 135 524 0 0 0 0 0 0 0 0 0 0
Totale 16.061